Latest receivables for 0R02.L: $29K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
VivoSim Labs posts a receivables of $29K as of June 2026. That compares with $32K in the prior-year period — down 9.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, VivoSim Labs's receivables was $32K. The latest reading is $29K — a 9.4% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
Receivables is one piece of VivoSim Labs's financial statement story. At $29K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for 0R02.L's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; VivoSim Labs's other metric pages and overview cover the third.
Judging VivoSim Labs against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $29K here, then scan peer and history charts to see if the gap is persistent.